Stromal cells are essential components of the bone marrow (BM) microenvironment that regulate and support the survival of different tumors, including chronic lymphocytic leukemia (CLL). In this study, we investigated the role of Notch signaling in the promotion of survival and chemoresistance of ...
The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial. The combination ...
Of these patients, 37% who were treated with the combination were negative for minimal residual disease (MRD) in the peripheral blood at 8 months. When testing the bone marrow, the MRD-negative rate was 32%. OncLive: Can you please provide an overview of your presentation on CLL at the ...
To be eligible for enrollment, patients needed to have an ECOG performance status of 0 or 1 and adequate bone marrow, organ, and cardiac function. Patients who experienced disease progression or who were not eligible for treatment with BTK inhibitors were eligible to enroll on the study. Findin...
In contrast to the usual findings in normal bone marrow, in CLL and low grade NHL CD4 positive cells were more numerous than CD8 positive cells. Whereas in NHL CDR were large and occupied all the nodule, in CLL were small and located in the center of the nodule. These findings can be ...
Such findings have the potential to impact patient care through risk stratification, treatment selection and drug discovery. However, this molecular map remains incomplete, with extant questions concerning the origin of the B-cell clone, the role of the TME, inter- and intra-compartmental ...
After treatment completion, a bone marrow (BM) aspirate/biopsy was recommended per protocol in case the patient achieved a complete remission (CR). Outcomes The primary objective of the study was to compare the efficacy of early versus deferred FCR in Binet stage A patients at high risk for ...
For patients who responded to treatment, MRD in bone marrow (BM) was assessed at cycle 9 and 3 months after end of treatment (EOT). The authors analyzed outcome according to known MRD risk groups, such as detectable and undetectable, as well as to known clinical and biological ...
Undetectable MRD in peripheral blood at any time was reported in 85.8% of those in the ibrutinib/venetoclax group vs 60.8% of the FCR group; undetectable MRD in bone marrow at any time was reported in 61.9% vs 40.3%. The adjusted odds ratios for undetectable MRD were 2.03 (95% ...
The accumulation of long-lived mature CD5+ B cells in peripheral blood (PB), bone marrow (BM), and secondary lymphoid organs (SLOs) is the hallmark of chronic lymphocytic leukemia (CLL).1, 2 In patients with the worst disease presentation, abnormalities in tissue homing and egress receptor ...